Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai
You may also be interested in...
Asia Spotlight: WuXi AppTec Senior VP Richard Soll On China’s Pharma Evolution
Soll talks about the transition of China’s top CRO from a preclinical play to an integrated services provider for innovative drug development.
WuXi AppTec SVP Richard Soll On China’s Pharma Evolution: An Interview With PharmAsia News
Soll talks about the transition of China’s top CRO from a preclinical play to an integrated services provider for innovative drug development.
WuXi Forms JV With PRA To Expand Clinical Services In China
WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.